NasdaqCM - Delayed Quote USD

ESSA Pharma Inc. (EPIX)

6.32 -0.40 (-5.95%)
At close: April 19 at 4:00 PM EDT
6.40 +0.08 (+1.27%)
After hours: April 19 at 7:32 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. David Ross Parkinson M.D. President, CEO & Director 814.15k -- 1950
Mr. David S. Wood C.M.A., CPA, CMA, CPA, M.B.A., MBA Chief Financial Officer 590.39k -- 1957
Mr. Peter A. Virsik M.B.A., M.S. Executive VP & COO 645.95k -- 1971
Dr. Alessandra Cesano M.D., Ph.D. Chief Medical Officer & Executive VP 623.93k -- 1961
Chandtip Chandhasin Executive -- -- --
Erica Osbourne Executive -- -- --
Erin Rudsinski Executive -- -- --
Loleta Harris Executive -- -- --
Neil Thapar Executive -- -- --
Nkengyal Barber Executive -- -- --

ESSA Pharma Inc.

999 West Broadway
Suite 720
Vancouver, BC V5Z 1K5
Canada
778 331 0962 https://www.essapharma.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
50

Description

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Corporate Governance

ESSA Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 07, 2024 - May 13, 2024
ESSA Pharma Inc. Earnings Call

Related Tickers

MSCL.TO Satellos Bioscience Inc.
0.5200
+6.12%
 
ENGN enGene Holdings Inc.
14.85
+4.79%
 
CRVS Corvus Pharmaceuticals, Inc.
1.4000
-0.71%
 
BETR.CN BetterLife Pharma Inc.
0.1050
+5.00%
 
ANTX AN2 Therapeutics, Inc.
2.4700
+3.78%
 
COGT Cogent Biosciences, Inc.
6.71
+1.51%
 
ANVS Annovis Bio, Inc.
10.06
+2.13%
 
RPHM Reneo Pharmaceuticals, Inc.
1.7400
-1.14%
 
COYA Coya Therapeutics, Inc.
8.00
-5.21%
 
RPTX Repare Therapeutics Inc.
3.1500
+4.30%